- CFO with proven track record will help lead transition to commercial company
Jeff Walsh to assume role of chief strategy officerJason Cole to assume role of chief operating and legal officer
“Chip’s deep knowledge of our industry and expertise in managing
financial and capital strategies are a strong addition to bluebird as we
prepare for commercialization and the potential European launch of our
first product in 2019,” said
“I am excited to join bluebird at such an important time in the company’s history with multiple potential product approvals on the horizon. The patient-focused mission, the extraordinary science and the bluebird culture made this a compelling opportunity,” said Mr. Baird. “I look forward to working with the team in a global commercial setting while continuing to invest in the science and the pipeline to deliver gene therapy to patients.”
Mr. Leschly added, “I want to thank Jeff for the strong foundation and financial position he’s put in place as our CFO, and I look forward to his continued partnership on advancing our growth strategies to ensure our existing and future potential products find their way to clinicians and patients globally. In addition, Jason’s leadership and track record of delivering results across many areas of our business make him ideally suited for a broader role inclusive of operations to help us scale across multiple product platforms and geographies.”
Chip Baird Biography
William D. “Chip” Baird has more than 20 years of financial and
strategic planning experience in the biopharmaceutical sector. For the
past seven years, Mr. Baird served as CFO of
Mr. Baird currently serves as a director of
About bluebird bio, Inc.
bluebird bio is pioneering gene therapy with purpose. From our
bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing.
bluebird bio has additional nests in
Follow bluebird bio on social media: @bluebirdbio,
LinkedIn,
Instagram
and
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the advancement of, and anticipated development and
commercialization plans for, the Company’s product candidates. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, the risks that the preliminary positive efficacy and safety results
from our prior and ongoing clinical trials of our product candidates
will not continue or be repeated in our ongoing or planned clinical
trials; risks that the current or planned clinical trials of our product
candidates will be insufficient to support future regulatory submissions
or to support marketing approval in the U.S. and EU; and the risk that
our product candidates will not be successfully developed, approved or
commercialized. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see the
section entitled “Risk Factors” in our most recent Form 10-Q as well as
discussions of potential risks, uncertainties and other important
factors in our subsequent filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20190211005213/en/
Source: bluebird bio, Inc.
Investors & Media
Investors:
Elizabeth Pingpank,
617-914-8736
epingpank@bluebirdbio.com
Media:
Stephanie Fagan, 201-572-9581
sfagan@bluebirdbio.com